Related Experiment Videos
Göteborg Metoprolol Trial: mortality and causes of death
Insights
Metoprolol significantly reduced all-cause mortality in patients compared to placebo over 3 months, 1 year, and 2 years. This beta-blocker demonstrated a consistent survival benefit across different time points in the study.
Area of Science:
- Cardiology
- Clinical Pharmacology
Background:
- Cardiovascular disease remains a leading cause of mortality worldwide.
- Beta-blockers, such as metoprolol, are commonly prescribed for various cardiac conditions.
- Understanding the long-term impact of metoprolol on overall survival is crucial for clinical practice.
Purpose of the Study:
- To evaluate the effect of metoprolol on all-cause mortality.
- To compare survival rates between patients treated with metoprolol and those receiving a placebo.
Main Methods:
- A randomized, double-blind, placebo-controlled trial was conducted.
- Patients received either metoprolol or a placebo during an initial 3-month blind treatment period.
- Mortality data were collected and analyzed at 3 months, 1 year, and 2 years.
Main Results:
- Metoprolol significantly reduced deaths compared to placebo at 3 months (40 vs. 62, p=0.024).
- This survival benefit persisted at 1 year (64 vs. 93, p=0.017) and 2 years (92 vs. 120, p=0.043).
- No significant difference in the relative incidence of specific causes of death was observed between groups.
Conclusions:
- Metoprolol effectively reduces all-cause mortality in patients.
- The observed mortality benefit of metoprolol is consistent across different follow-up periods.
- Metoprolol appears to lower overall mortality without altering the pattern of specific causes of death.
Abstract:
During the 3-month blind treatment period there were 40 deaths in the metoprolol group compared with 62 deaths in the placebo group (p = 0.024). During the first year (after 3 months the 2 groups were treated similarly) there were 64 deaths in the metoprolol group vs 93 in the placebo group (p = 0.017) and during 2 years 92 patients died in the metoprolol group vs 120 in the placebo group (p = 0.043). The relative incidence of different causes of death did not differ significantly between the 2 treatment groups, indicating that metoprolol reduced all causes of death to the same extent as its effect on overall mortality.